Entos Pharmaceuticals

Entos Pharmaceuticals is committed to developing the next generation of nucleic acid-based therapies using its proprietary Fusogenix drug delivery system. Fusogenix employs a novel mechanism of action to deliver intact and unmodified molecules directly into the cytosol of target cells. The technology is applicable to various types of treatments, including gene therapy, mRNA, miRNA, RNAi, and CRISPR.